These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

121 related articles for article (PubMed ID: 38374744)

  • 1. Vortioxetine Treatment for Depression in Patients with Prodromal vs Mild Alzheimer's Disease: A Six-Month, Open-Label, Observational Study.
    Padovani A; Caratozzolo S; Benussi A; Galli A; Rozzini L; Cosseddu M; Turrone R; Pilotto A
    J Prev Alzheimers Dis; 2024; 11(2):375-381. PubMed ID: 38374744
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Treatment Effects of Vortioxetine on Cognitive Functions in Mild Alzheimer's Disease Patients with Depressive Symptoms: A 12 Month, Open-Label, Observational Study.
    Cumbo E; Cumbo S; Torregrossa S; Migliore D
    J Prev Alzheimers Dis; 2019; 6(3):192-197. PubMed ID: 31062834
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A pilot randomized controlled trial evaluating an integrated treatment of rivastigmine transdermal patch and cognitive stimulation in patients with Alzheimer's disease.
    D'Onofrio G; Sancarlo D; Addante F; Ciccone F; Cascavilla L; Paris F; Elia AC; Nuzzaci C; Picoco M; Greco A; Panza F; Pilotto A
    Int J Geriatr Psychiatry; 2015 Sep; 30(9):965-75. PubMed ID: 25504466
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Effects of rivastigmine treatment on the neuropsychiatric and behavioral disturbances of nursing home residents with moderate to severe probable Alzheimer's disease: a 26-week, multicenter, open-label study.
    Cummings JL; Koumaras B; Chen M; Mirski D;
    Am J Geriatr Pharmacother; 2005 Sep; 3(3):137-48. PubMed ID: 16257816
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Facial emotion recognition is associated with executive functions and depression scores, but not staging of dementia, in mild-to-moderate Alzheimer's disease.
    Buçgün İ; Korkmaz ŞA; Öyekçin DG
    Brain Behav; 2024 Jan; 14(1):e3390. PubMed ID: 38376045
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Atorvastatin therapy lowers circulating cholesterol but not free radical activity in advance of identifiable clinical benefit in the treatment of mild-to-moderate AD.
    Sparks DL; Sabbagh MN; Connor DJ; Lopez J; Launer LJ; Petanceska S; Browne P; Wassar D; Johnson-Traver S; Lochhead J; Ziolkowski C
    Curr Alzheimer Res; 2005 Jul; 2(3):343-53. PubMed ID: 15974900
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Donepezil for dementia due to Alzheimer's disease.
    Birks JS; Harvey RJ
    Cochrane Database Syst Rev; 2018 Jun; 6(6):CD001190. PubMed ID: 29923184
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Souvenaid for Alzheimer's disease.
    Burckhardt M; Watzke S; Wienke A; Langer G; Fink A
    Cochrane Database Syst Rev; 2020 Dec; 12(12):CD011679. PubMed ID: 33320335
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Fortasyn Connect Improves Neuropsychiatric Symptoms in Patients with Mild Cognitive Impairment and Dementia: Results from a Retrospective Real-World Study.
    Aguilar-Barberà M; Soler-Girabau P; Tabuenca-Martín AI; Prieto-Del Val L
    J Alzheimers Dis; 2023; 93(2):621-631. PubMed ID: 37066911
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Patient and caregiver outcomes after 6 +/- 1.5-months of rivastigmine therapy for mild-to-moderate Alzheimer's disease: the Belgian FExT study.
    Mets T; Vandewoude M; Jacquy J; Deblander A; MacDonald K; Sloesen A; Abraham I;
    Curr Med Res Opin; 2007 Oct; 23(10):2485-501. PubMed ID: 17784995
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effects of donepezil, galantamine and rivastigmine in 938 Italian patients with Alzheimer's disease: a prospective, observational study.
    Santoro A; Siviero P; Minicuci N; Bellavista E; Mishto M; Olivieri F; Marchegiani F; Chiamenti AM; Benussi L; Ghidoni R; Nacmias B; Bagnoli S; Ginestroni A; Scarpino O; Feraco E; Gianni W; Cruciani G; Paganelli R; Di Iorio A; Scognamiglio M; Grimaldi LM; Gabelli C; Sorbi S; Binetti G; Crepaldi G; Franceschi C
    CNS Drugs; 2010 Feb; 24(2):163-76. PubMed ID: 20088621
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The ASCOMALVA trial: association between the cholinesterase inhibitor donepezil and the cholinergic precursor choline alphoscerate in Alzheimer's disease with cerebrovascular injury: interim results.
    Amenta F; Carotenuto A; Fasanaro AM; Rea R; Traini E
    J Neurol Sci; 2012 Nov; 322(1-2):96-101. PubMed ID: 22959283
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Memantine for dementia.
    McShane R; Westby MJ; Roberts E; Minakaran N; Schneider L; Farrimond LE; Maayan N; Ware J; Debarros J
    Cochrane Database Syst Rev; 2019 Mar; 3(3):CD003154. PubMed ID: 30891742
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Neuropsychiatric Symptoms in Alzheimer's Disease Are the Main Determinants of Functional Impairment in Advanced Everyday Activities.
    Delgado C; Vergara RC; Martínez M; Musa G; Henríquez F; Slachevsky A
    J Alzheimers Dis; 2019; 67(1):381-392. PubMed ID: 30584142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Gender Differences in Neuropsychiatric Symptoms in Mild to Moderate Alzheimer's Disease Patients Undergoing Switch of Cholinesterase Inhibitors: A Post Hoc Analysis of the EVOLUTION Study.
    Colombo D; Caltagirone C; Padovani A; Sorbi S; Spalletta G; Simoni L; Ori A; Zagni E
    J Womens Health (Larchmt); 2018 Nov; 27(11):1368-1377. PubMed ID: 30085899
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determinants of the quality of life in Alzheimer's disease patients as assessed by the Japanese version of the Quality of Life-Alzheimer's disease scale.
    Matsui T; Nakaaki S; Murata Y; Sato J; Shinagawa Y; Tatsumi H; Furukawa TA
    Dement Geriatr Cogn Disord; 2006; 21(3):182-91. PubMed ID: 16401890
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Efficacy of Transcranial Direct Current Stimulation Combined with Cognitive Training in the Treatment of Apathy in Patients with Alzheimer's Disease: Study Protocol for a Randomized Trial.
    Nguyen JP; Boutoleau-Bretonniere C; Lefaucheur JP; Suarez A; Gaillard H; Chapelet G; Abad S; Van Langhenhove A; Nizard J; de Decker L
    Rev Recent Clin Trials; 2018; 13(4):319-327. PubMed ID: 29658441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the efficacy, safety and tolerability of orally administered BI 409306, a novel phosphodiesterase type 9 inhibitor, in two randomised controlled phase II studies in patients with prodromal and mild Alzheimer's disease.
    Frölich L; Wunderlich G; Thamer C; Roehrle M; Garcia M; Dubois B
    Alzheimers Res Ther; 2019 Feb; 11(1):18. PubMed ID: 30755255
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Risperidone, olanzapine and quetiapine in the treatment of behavioral and psychological symptoms in patients with Alzheimer's disease: preliminary findings from a naturalistic, retrospective study.
    Rocca P; Marino F; Montemagni C; Perrone D; Bogetto F
    Psychiatry Clin Neurosci; 2007 Dec; 61(6):622-9. PubMed ID: 18081622
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cognitive improvement in mild to moderate Alzheimer's dementia after treatment with the acetylcholine precursor choline alfoscerate: a multicenter, double-blind, randomized, placebo-controlled trial.
    De Jesus Moreno Moreno M
    Clin Ther; 2003 Jan; 25(1):178-93. PubMed ID: 12637119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.